MT-2 · 10 mg / vial- ·3 mL bacteriostatic water
- ·10 × 1 mL insulin syringes
- ·Alcohol swabs
Melanotan II 10 mg
Melanocortin-receptor agonist — cyclic heptapeptide.
Melanotan II is a synthetic cyclic heptapeptide non-selective melanocortin-receptor agonist (MC1R / MC3R / MC4R / MC5R).
What the peptide is.
Melanotan II was originally developed at the University of Arizona as a more potent, longer-acting analogue of α-MSH. The cyclic structure confers metabolic stability not present in native α-MSH.
Historical Phase 1 trials evaluated MT-II for photoprotection research. No progression to approved therapeutic use. MT-1 (afamelanotide) is the related linear analogue that reached approval for erythropoietic protoporphyria in specific jurisdictions.
Non-selective agonism at melanocortin receptors MC1R, MC3R, MC4R, MC5R. MC1R activation modulates melanogenesis in melanocytes.
Reconstitution, storage, and handling.
Lab-technical guidance for the researcher handling the material. Not therapeutic dosing, not administration guidance — those are not within the scope of this supply.
- Recommended solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- Inject diluent slowly down the side of the vial onto the cake.
- Swirl gently — do not shake.
- Solution should be clear and colourless. Discard if not.
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life · sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
- Shelf life · reconstituted
- Up to 4 weeks refrigerated.
- ▸Stable lyophilised. Standard peptide handling.
This lot, documented.
Every shipment is accompanied by a signed four-page analytical report including the HPLC chromatogram, ESI-MS spectrum, purity calculation, and sample handling chain-of-custody.
The report you will receive is specific to the lot dispatched to you. The display below is a current representative example.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
REPORT ID JA-26-04-012
SUBJECT Melanotan II 10 mg
DESIGNATION MT-2
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 99.00
MASS EXP. 1024.18 Da
MASS OBS. 1024.20 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11Research references for Melanotan II 10 mg.
1 peer-reviewed publications. Links resolve to PubMed. DOIs are provided where available.
- [01]Dorr RT, Lines R, Levine N, et al.
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide
Life Sciences · 1996
- Q.How does this differ from MT-1 (afamelanotide)?
- A.MT-1 is a linear α-MSH analogue with MC1R selectivity and has reached approval for a narrow therapeutic indication (erythropoietic protoporphyria). MT-II is a cyclic non-selective melanocortin agonist — research use only.
This peptide is supplied by Omega Grade for in vitro laboratory research use. It is not a drug, food, cosmetic, or dietary supplement. It is not approved by the FDA, EMA, MHRA, PMDA, or any other regulatory authority for any therapeutic indication.
No claim of therapeutic benefit is made or implied. The material is not intended for human or veterinary consumption, administration, or any form of self-experimentation. By purchasing, you acknowledge the researcher terms and accept full responsibility for local import compliance and all handling.
